Trials / Withdrawn
WithdrawnNCT00914433
Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of Inhaled TPI 1100 in Healthy Volunteers
A Phase 1,Randomized, Double--blind, Placebo-controlled Study Assessing the Safety and Tolerability, the Pharmacodynamics and Pharmacokinetics of Single-ascending and Repeated Doses of Inhaled TPI 1100 in Healthy Subjects
- Status
- Withdrawn
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 0 (actual)
- Sponsor
- Syntara · Industry
- Sex
- All
- Age
- 18 Years – 55 Years
- Healthy volunteers
- Accepted
Summary
This study will look at the safety and tolerability of TPI 1100 in healthy volunteers and look at pharmacodynamic (PD) effect on mRNA expression of PDE 4B/D \& 7A in blood and in sputum.
Detailed description
Study was not initiated and terminated before start-up.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | TPI 1100 | 1 dose only increasing dose |
Timeline
- Start date
- 2009-04-01
- Primary completion
- 2009-12-01
- Completion
- 2010-04-01
- First posted
- 2009-06-05
- Last updated
- 2012-12-03
Source: ClinicalTrials.gov record NCT00914433. Inclusion in this directory is not an endorsement.